SATELLITE SESSION 2: Helsinki, Finland | 22nd Jun 2025
On-demand from the European Academy of Neurology 2025 Satellite Symposium, please enjoy this educational session provided by global experts in the field of generalized myasthenia gravis – Prof. Francesco Saccà (Italy), Prof. Heinz Wiendl (Germany), & Prof. Elena Saccani (Italy).
Symposium Objectives- Explore long-term evidence for the efficacy and safety of ravulizumab and eculizumab as treatments for anti-acetylcholine receptor antibody-positive (AChR-Ab+) gMG in clinical trial and real-world settings
- Review current guidelines and unmet needs in gMG treatment
- Discuss real-world experience for patients being treated with biologics
- Review challenges that patients experience as they navigate diagnosis and treatment
Prof. Heinz Wiendl
Director, Professor
Neurology University Hospital,
Muenster, Germany
Prof. Heinz Wiendl
Professor Wiendl studied medicine in Germany, Switzerland, and the USA, graduating in 1996. After working as a research fellow at the Institute of Neuroanatomy, Nuremberg, and the Max Planck Institute for Neurobiology and the Department of Neurology, Tuebingen, he became head of the clinical research group for multiple sclerosis (MS) in Wuerzburg in 2005 and acted as a vice-chair of the Department of Neurology.
In 2010, he was recruited to Muenster University Hospital as director of the Department of Neurology – Inflammatory Disorders of the Nervous System and Neurooncology. Since 2013, he serves as Head of the Department of Neurology, Muenster – to which the Institute of Translational Neurology has been associated since 2018.
His research focusses on inflammatory neurodegeneration and immune regulation and protection as well as monitoring MS and its therapy. His achievements have been recognized by both Sobek awards of the German Society for MS (DMSG) (2004; 2015). In 2017, Heinz Wiendl was appointed Honorary Professor at Sydney Medical School. Masshad University awarded him the title of Honorary Doctor and Honorary Professor in 2021.
Professor Wiendl is a member of numerous scientific and academic advisory boards and expert panels, including editorial boards of international scientific journals in the fields of neurology, neurosciences, and immunology, as well as for societies, foundations, and project promoters. Currently, he is the speaker of the Collaborative Research Center 128 "Multiple Sclerosis", and speaker of the Competence Network Multiple Sclerosis (KKNMS).
Furthermore, he was appointed fellow of the American and the European Academy of Neurology in 2019. Until 2016, Heinz Wiendl was Vice Dean for Research of the Medical Faculty in Muenster. He is founder and principal investigator of the "Body and Brain Institute" Muenster, a prestigious research building funded by the German Federal Ministry.
Professor Wiendl served as a PI for or coordinated through membership of steering committees ≥40 phase I-IV clinical trials. Since 1998, he has authored more than 650 peer-reviewed publications in high-impact journals such as Nature Medicine, Journal of Experimental Medicine, Blood, Annals of Neurology, BRAIN, Neurology, Nature Neuroscience, Immunity (H index = 77, approx. 1,500 citations/year), 4 books (editor), several book chapters.
Prof. Elena Saccani
Professor
Azienda Ospedaliero-Universitaria di Parma,
Parma, Italy
Prof. Elena Saccani
Prof. Elena Saccani is a neurologist at the Azienda Ospedaliero-Universitaria di Parma, where she has been working since November 2019, particularly focusing on neuromuscular diseases. Her clinical activities include performing electromyographic and neuropathological diagnostics (muscle, nerve, and skin biopsies).
She graduated in Medicine and Surgery in 2008 and specialized in Neurology in 2016, both at the University of Parma. Between 2018 and 2019, she completed a second-level Master's degree in "Diagnosis, Treatment, and Research of Neuromuscular Diseases" at the University of Milan.
Since 2021, she has been a contract professor for the Physiotherapy Degree Course at the University of Parma, where she teaches courses on peripheral nervous system diseases and neuromuscular diseases. She is the co-author of indexed scientific publications in peer-reviewed journals and has participated in international scientific congresses, contributing to multicentric research projects on motor neuron diseases, neuromuscular junction diseases, and muscle diseases. She has also served as a speaker and moderator in training courses and scientific meetings, with a specific focus on neuromyopathology and neurophysiology.
Dr. Saccani has been registered with the Order of Physicians and Dentists of Reggio Emilia since 2009 and is a member of professional associations, including the Italian Association of Myology (AIM) and the Italian Society of Neurology (SIN).
Prof. Francesco Saccà
Professor
Dipartimento di Neuroscienze
Università degli Studi di Napoli “Federico II”
Napoli, Italy
Prof. Francesco Saccà
Prof. Francesco Saccà is a physician with 21 years of clinical experience since graduating from the University of Naples Federico II. He is amongst the top researchers globally in the field of Neurology and his research activities include authoring scientific publications, treatment guidelines, clinical trials and congresses, focusing on diseases such as Generalized Myasthenia Gravis, Neuromuscular Junction Diseases, Nervous System Diseases and Hereditary Ataxias.
He currently holds a role as Assistant Professor in Neurology at the University of Naples Federico II since 2011 and Assistant Medical Director at the AOU Federico II, Naples, Italy since 2012.
Prof. Saccà has been a co-author on numerous publications in gMG and other neurological disorders and also participated in the ‘Expert Consensus Recommendations for Improving and Standardising the Assessment of Patients with Generalized Myasthenia Gravis’ alongside the MG Collegium Sub-committee that was published in the European Journal of Neurology.
healthcare professional
SOLIRIS® (eculizumab) is indicated for the treatment of refractory generalised myasthenia gravis (gMG) in patients aged 6 years and above who are anti-acetylcholine receptor (AChR) antibody-positive.
ULTOMIRIS® (ravulizumab) is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody-positive.
Ravulizumab EU Summary of Product Characteristics
Eculizumab EU Summary of Product Characteristics
Prescribing information may differ from country to country. Please refer to your locally approved label and take this into consideration when viewing this information.
Please verify reimbursement status applicable in your country.
Please report any adverse reactions via your national reporting system. Adverse events can also be reported to Alexion pharmaceuticals by the following email: https://contactazmedical.astrazeneca.com/